miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication

Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Cell death & disease 2023-10, Vol.14 (10), p.687-687, Article 687
Main Authors: Fuertes, Teresa, Álvarez-Corrales, Emigdio, Gómez-Escolar, Carmen, Ubieto-Capella, Patricia, Serrano-Navarro, Álvaro, de Molina, Antonio, Méndez, Juan, Ramiro, Almudena R., de Yébenes, Virginia G.
Format: Article
Language:English
Subjects:
13/31
14/35
38
38/77
38/91
42
42/44
631/154/556
631/250/1932
631/67/1059/602
64/60
82
82/29
96
96/2
Antibodies
B-cell lymphoma
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Culture
Chemotherapy
Combination therapy
Deoxyribonucleic acid
DNA
DNA biosynthesis
Immunology
Kinases
Life Sciences
Lymphoma
MicroRNAs
miRNA
Non-Hodgkin's lymphoma
Protein-tyrosine kinase
Replication
Tumor suppressor genes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3
cites cdi_FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3
container_end_page 687
container_issue 10
container_start_page 687
container_title Cell death & disease
container_volume 14
creator Fuertes, Teresa
Álvarez-Corrales, Emigdio
Gómez-Escolar, Carmen
Ubieto-Capella, Patricia
Serrano-Navarro, Álvaro
de Molina, Antonio
Méndez, Juan
Ramiro, Almudena R.
de Yébenes, Virginia G.
description Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic potential of the tumor suppressor microRNA-28 (miR-28) for DLBCL, alone and in combination with the Bruton’s tyrosine kinase inhibitor ibrutinib. Combination therapy with miR-28 plus ibrutinib potentiated the anti-tumor effects of monotherapy with either agent by inducing a specific transcriptional cell-cycle arrest program that impairs DNA replication. The molecular actions of miR-28 and ibrutinib synergistically impair DNA replication by simultaneous inhibition of origin activation and fork progression. Moreover, we found that downregulation of the miR-28-plus-ibrutinib gene signature correlates with better survival of ABC-DLBCL patients. These results provide evidence for the effectiveness of a new miRNA-based ibrutinib combination therapy for DLBCL and unveil the miR-28-plus-ibrutinib gene signature as a new predictor of outcome in ABC-DLBCL patients.
doi_str_mv 10.1038/s41419-023-06178-0
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9379e2de340e481cb06088a6a79cb0c0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9379e2de340e481cb06088a6a79cb0c0</doaj_id><sourcerecordid>2878558000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEotXSP8DJEhcugbEdx_YJlZaPShVICM6W7UyyXiVxsLOt9t-T7FZAOeCLZ-x5H1szb1G8pPCGAldvc0UrqktgvISaSlXCk-KcQUXLSin99K_4rLjIeQfL4hyYqJ8XZ1wqwbTQ50U7hG8lU6WzGRvi4-DCaOcQRzJvMdnpQMIw2ZAysV2XMOdwh-Q98dj3pD8M0zYOlnQp3s9b4g4k4X1IYezI9ZfLJZn64I-0F8Wz1vYZLx72TfHj44fvV5_L26-fbq4ub0svqJpL14KqWM2sk3XtvOCqkm0DTnDWKuWcRCVahZpJJ7yTzmuBgiJQzoXUjeWb4ubEbaLdmSmFwaaDiTaY40FMnbFpDr5Ho7nUyBrkFWClqHdQg1K2tlIvsYeF9e7EmvZuwMbjOCfbP4I-vhnD1nTxzlAQSgDUC-H1AyHFn3vMsxlCXltnR4z7bJiSugIh-frYq39Kd3GfxqVXa5USQq3z2xTsVOVTzDlh-_s3FMxqC3OyhVlsYY62MKuIn0R5WkeD6Q_6P6pfBvG4_w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878558000</pqid></control><display><type>article</type><title>miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Fuertes, Teresa ; Álvarez-Corrales, Emigdio ; Gómez-Escolar, Carmen ; Ubieto-Capella, Patricia ; Serrano-Navarro, Álvaro ; de Molina, Antonio ; Méndez, Juan ; Ramiro, Almudena R. ; de Yébenes, Virginia G.</creator><creatorcontrib>Fuertes, Teresa ; Álvarez-Corrales, Emigdio ; Gómez-Escolar, Carmen ; Ubieto-Capella, Patricia ; Serrano-Navarro, Álvaro ; de Molina, Antonio ; Méndez, Juan ; Ramiro, Almudena R. ; de Yébenes, Virginia G.</creatorcontrib><description>Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic potential of the tumor suppressor microRNA-28 (miR-28) for DLBCL, alone and in combination with the Bruton’s tyrosine kinase inhibitor ibrutinib. Combination therapy with miR-28 plus ibrutinib potentiated the anti-tumor effects of monotherapy with either agent by inducing a specific transcriptional cell-cycle arrest program that impairs DNA replication. The molecular actions of miR-28 and ibrutinib synergistically impair DNA replication by simultaneous inhibition of origin activation and fork progression. Moreover, we found that downregulation of the miR-28-plus-ibrutinib gene signature correlates with better survival of ABC-DLBCL patients. These results provide evidence for the effectiveness of a new miRNA-based ibrutinib combination therapy for DLBCL and unveil the miR-28-plus-ibrutinib gene signature as a new predictor of outcome in ABC-DLBCL patients.</description><identifier>ISSN: 2041-4889</identifier><identifier>EISSN: 2041-4889</identifier><identifier>DOI: 10.1038/s41419-023-06178-0</identifier><identifier>PMID: 37852959</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/31 ; 14/35 ; 38 ; 38/77 ; 38/91 ; 42 ; 42/44 ; 631/154/556 ; 631/250/1932 ; 631/67/1059/602 ; 64/60 ; 82 ; 82/29 ; 96 ; 96/2 ; Antibodies ; B-cell lymphoma ; Biochemistry ; Biomedical and Life Sciences ; Cell Biology ; Cell Culture ; Chemotherapy ; Combination therapy ; Deoxyribonucleic acid ; DNA ; DNA biosynthesis ; Immunology ; Kinases ; Life Sciences ; Lymphoma ; MicroRNAs ; miRNA ; Non-Hodgkin's lymphoma ; Protein-tyrosine kinase ; Replication ; Tumor suppressor genes ; Tumors</subject><ispartof>Cell death &amp; disease, 2023-10, Vol.14 (10), p.687-687, Article 687</ispartof><rights>The Author(s) 2023</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3</citedby><cites>FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3</cites><orcidid>0000-0002-3785-5868 ; 0000-0002-3235-2559</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2878558000/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2878558000?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids></links><search><creatorcontrib>Fuertes, Teresa</creatorcontrib><creatorcontrib>Álvarez-Corrales, Emigdio</creatorcontrib><creatorcontrib>Gómez-Escolar, Carmen</creatorcontrib><creatorcontrib>Ubieto-Capella, Patricia</creatorcontrib><creatorcontrib>Serrano-Navarro, Álvaro</creatorcontrib><creatorcontrib>de Molina, Antonio</creatorcontrib><creatorcontrib>Méndez, Juan</creatorcontrib><creatorcontrib>Ramiro, Almudena R.</creatorcontrib><creatorcontrib>de Yébenes, Virginia G.</creatorcontrib><title>miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication</title><title>Cell death &amp; disease</title><addtitle>Cell Death Dis</addtitle><description>Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic potential of the tumor suppressor microRNA-28 (miR-28) for DLBCL, alone and in combination with the Bruton’s tyrosine kinase inhibitor ibrutinib. Combination therapy with miR-28 plus ibrutinib potentiated the anti-tumor effects of monotherapy with either agent by inducing a specific transcriptional cell-cycle arrest program that impairs DNA replication. The molecular actions of miR-28 and ibrutinib synergistically impair DNA replication by simultaneous inhibition of origin activation and fork progression. Moreover, we found that downregulation of the miR-28-plus-ibrutinib gene signature correlates with better survival of ABC-DLBCL patients. These results provide evidence for the effectiveness of a new miRNA-based ibrutinib combination therapy for DLBCL and unveil the miR-28-plus-ibrutinib gene signature as a new predictor of outcome in ABC-DLBCL patients.</description><subject>13/31</subject><subject>14/35</subject><subject>38</subject><subject>38/77</subject><subject>38/91</subject><subject>42</subject><subject>42/44</subject><subject>631/154/556</subject><subject>631/250/1932</subject><subject>631/67/1059/602</subject><subject>64/60</subject><subject>82</subject><subject>82/29</subject><subject>96</subject><subject>96/2</subject><subject>Antibodies</subject><subject>B-cell lymphoma</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Cell Biology</subject><subject>Cell Culture</subject><subject>Chemotherapy</subject><subject>Combination therapy</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA biosynthesis</subject><subject>Immunology</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Lymphoma</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Protein-tyrosine kinase</subject><subject>Replication</subject><subject>Tumor suppressor genes</subject><subject>Tumors</subject><issn>2041-4889</issn><issn>2041-4889</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhiMEotXSP8DJEhcugbEdx_YJlZaPShVICM6W7UyyXiVxsLOt9t-T7FZAOeCLZ-x5H1szb1G8pPCGAldvc0UrqktgvISaSlXCk-KcQUXLSin99K_4rLjIeQfL4hyYqJ8XZ1wqwbTQ50U7hG8lU6WzGRvi4-DCaOcQRzJvMdnpQMIw2ZAysV2XMOdwh-Q98dj3pD8M0zYOlnQp3s9b4g4k4X1IYezI9ZfLJZn64I-0F8Wz1vYZLx72TfHj44fvV5_L26-fbq4ub0svqJpL14KqWM2sk3XtvOCqkm0DTnDWKuWcRCVahZpJJ7yTzmuBgiJQzoXUjeWb4ubEbaLdmSmFwaaDiTaY40FMnbFpDr5Ho7nUyBrkFWClqHdQg1K2tlIvsYeF9e7EmvZuwMbjOCfbP4I-vhnD1nTxzlAQSgDUC-H1AyHFn3vMsxlCXltnR4z7bJiSugIh-frYq39Kd3GfxqVXa5USQq3z2xTsVOVTzDlh-_s3FMxqC3OyhVlsYY62MKuIn0R5WkeD6Q_6P6pfBvG4_w</recordid><startdate>20231018</startdate><enddate>20231018</enddate><creator>Fuertes, Teresa</creator><creator>Álvarez-Corrales, Emigdio</creator><creator>Gómez-Escolar, Carmen</creator><creator>Ubieto-Capella, Patricia</creator><creator>Serrano-Navarro, Álvaro</creator><creator>de Molina, Antonio</creator><creator>Méndez, Juan</creator><creator>Ramiro, Almudena R.</creator><creator>de Yébenes, Virginia G.</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3785-5868</orcidid><orcidid>https://orcid.org/0000-0002-3235-2559</orcidid></search><sort><creationdate>20231018</creationdate><title>miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication</title><author>Fuertes, Teresa ; Álvarez-Corrales, Emigdio ; Gómez-Escolar, Carmen ; Ubieto-Capella, Patricia ; Serrano-Navarro, Álvaro ; de Molina, Antonio ; Méndez, Juan ; Ramiro, Almudena R. ; de Yébenes, Virginia G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>13/31</topic><topic>14/35</topic><topic>38</topic><topic>38/77</topic><topic>38/91</topic><topic>42</topic><topic>42/44</topic><topic>631/154/556</topic><topic>631/250/1932</topic><topic>631/67/1059/602</topic><topic>64/60</topic><topic>82</topic><topic>82/29</topic><topic>96</topic><topic>96/2</topic><topic>Antibodies</topic><topic>B-cell lymphoma</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Cell Biology</topic><topic>Cell Culture</topic><topic>Chemotherapy</topic><topic>Combination therapy</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA biosynthesis</topic><topic>Immunology</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Lymphoma</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Protein-tyrosine kinase</topic><topic>Replication</topic><topic>Tumor suppressor genes</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuertes, Teresa</creatorcontrib><creatorcontrib>Álvarez-Corrales, Emigdio</creatorcontrib><creatorcontrib>Gómez-Escolar, Carmen</creatorcontrib><creatorcontrib>Ubieto-Capella, Patricia</creatorcontrib><creatorcontrib>Serrano-Navarro, Álvaro</creatorcontrib><creatorcontrib>de Molina, Antonio</creatorcontrib><creatorcontrib>Méndez, Juan</creatorcontrib><creatorcontrib>Ramiro, Almudena R.</creatorcontrib><creatorcontrib>de Yébenes, Virginia G.</creatorcontrib><collection>SpringerOpen</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cell death &amp; disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuertes, Teresa</au><au>Álvarez-Corrales, Emigdio</au><au>Gómez-Escolar, Carmen</au><au>Ubieto-Capella, Patricia</au><au>Serrano-Navarro, Álvaro</au><au>de Molina, Antonio</au><au>Méndez, Juan</au><au>Ramiro, Almudena R.</au><au>de Yébenes, Virginia G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication</atitle><jtitle>Cell death &amp; disease</jtitle><stitle>Cell Death Dis</stitle><date>2023-10-18</date><risdate>2023</risdate><volume>14</volume><issue>10</issue><spage>687</spage><epage>687</epage><pages>687-687</pages><artnum>687</artnum><issn>2041-4889</issn><eissn>2041-4889</eissn><abstract>Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic potential of the tumor suppressor microRNA-28 (miR-28) for DLBCL, alone and in combination with the Bruton’s tyrosine kinase inhibitor ibrutinib. Combination therapy with miR-28 plus ibrutinib potentiated the anti-tumor effects of monotherapy with either agent by inducing a specific transcriptional cell-cycle arrest program that impairs DNA replication. The molecular actions of miR-28 and ibrutinib synergistically impair DNA replication by simultaneous inhibition of origin activation and fork progression. Moreover, we found that downregulation of the miR-28-plus-ibrutinib gene signature correlates with better survival of ABC-DLBCL patients. These results provide evidence for the effectiveness of a new miRNA-based ibrutinib combination therapy for DLBCL and unveil the miR-28-plus-ibrutinib gene signature as a new predictor of outcome in ABC-DLBCL patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37852959</pmid><doi>10.1038/s41419-023-06178-0</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3785-5868</orcidid><orcidid>https://orcid.org/0000-0002-3235-2559</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2041-4889
ispartof Cell death & disease, 2023-10, Vol.14 (10), p.687-687, Article 687
issn 2041-4889
2041-4889
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9379e2de340e481cb06088a6a79cb0c0
source Publicly Available Content Database; PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 13/31
14/35
38
38/77
38/91
42
42/44
631/154/556
631/250/1932
631/67/1059/602
64/60
82
82/29
96
96/2
Antibodies
B-cell lymphoma
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Culture
Chemotherapy
Combination therapy
Deoxyribonucleic acid
DNA
DNA biosynthesis
Immunology
Kinases
Life Sciences
Lymphoma
MicroRNAs
miRNA
Non-Hodgkin's lymphoma
Protein-tyrosine kinase
Replication
Tumor suppressor genes
Tumors
title miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A00%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-28-based%20combination%20therapy%20impairs%20aggressive%20B%20cell%20lymphoma%20growth%20by%20rewiring%20DNA%20replication&rft.jtitle=Cell%20death%20&%20disease&rft.au=Fuertes,%20Teresa&rft.date=2023-10-18&rft.volume=14&rft.issue=10&rft.spage=687&rft.epage=687&rft.pages=687-687&rft.artnum=687&rft.issn=2041-4889&rft.eissn=2041-4889&rft_id=info:doi/10.1038/s41419-023-06178-0&rft_dat=%3Cproquest_doaj_%3E2878558000%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c518t-bf084262ab766bc53847fd0b532f88bb7e85f8e927b5cb7bc95e51e0133579da3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2878558000&rft_id=info:pmid/37852959&rfr_iscdi=true